Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
, 28 (3), 179-203

Evidence-based Guidelines for the Pharmacological Management of Attention Deficit Hyperactivity Disorder: Update on Recommendations From the British Association for Psychopharmacology

Affiliations
Practice Guideline

Evidence-based Guidelines for the Pharmacological Management of Attention Deficit Hyperactivity Disorder: Update on Recommendations From the British Association for Psychopharmacology

Blanca Bolea-Alamañac et al. J Psychopharmacol.

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common condition with a high societal burden. The present guidelines summarise current literature, generating expert consensus recommendations for the treatment of ADHD in children and adults. These guidelines also provide a review of recent research in the fields of neuroimaging, neuropsychology and genetics of ADHD. Novel discoveries in these areas have informed physiological models for the disease. Since the publication of the previous British Association for Psychopharmacology guidelines in 2008, new drugs have been licensed and further compounds are being investigated. The publication of randomised controlled trials of psychological interventions has contributed to the range of treatment options for ADHD. As the disorder has been diagnosed more frequently there has been greater focus on comorbid conditions and how they impact treatment. Services have continued to develop for the treatment of ADHD in adults and care agreements have been introduced to facilitate access to treatment.

Keywords: ADD; ADHD; BAP; attention deficit and hyperactivity disorder; hyperkinetic disorder.

Similar articles

See all similar articles

Cited by 44 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback